Great Point Partners’s ChemoCentryx, Inc. CCXI Stock Holding History

Great Point Partners’s Portfolio CCXI Stock Details CCXI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-253,230	Closed	-$13.9M	–	46
2020 Q3	$13.9M	Buy	+253,230	New	+$13.6M	1.25%	20
2020 Q2	–	Sell	-357,379	Closed	-$14.4M	–	43
2020 Q1	$14.4M	Buy	+357,379	New	+$15.2M	1.5%	21
2014 Q4	–	Sell	-483,741	Closed	-$2.18M	–	40
2014 Q3	$2.18M	Buy	+483,741	New	+$2.56M	0.94%	28
2014 Q2	–	Sell	-249,700	Closed	-$1.66M	–	45
2014 Q1	$1.66M	Sell	249,700 -750,300	-75%	-$5.21M	0.86%	30
2013 Q4	$5.79M	Buy	+1,000,000	New	+$5.16M	4.09%	8

Other funds holding CCXI

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PAMU

Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Great Point Partners's CCXI Position: Q4 2020 in Review

Great Point Partners sold out of ChemoCentryx, Inc. (CCXI) in Q4 2020, closing a stake of 253,230 shares — an estimated $13.9M sold.

Great Point Partners first reported a position in CCXI in Q4 2013 and held it in 5 quarters. The position peaked at $14.4M in Q1 2020. 196 funds tracked by Wall St. Rank hold CCXI as of Q4 2020.

Great Point Partners reported no remaining ChemoCentryx, Inc. position as of Q4 2020 after selling out during the quarter.
Great Point Partners sold 253,230 ChemoCentryx, Inc. shares in Q4 2020, an estimated $13.9M.
Great Point Partners first reported a position in ChemoCentryx, Inc. in Q4 2013 and held it in 5 quarters.
Great Point Partners's ChemoCentryx, Inc. position peaked at $14.4M in Q1 2020.
196 funds tracked by Wall St. Rank held ChemoCentryx, Inc. as of Q4 2020.

Based on Great Point Partners's 13F filing for Q4 2020, filed 16 Feb 2021.